11:10 AM EDT, 04/30/2025 (MT Newswires) -- CFRA, an independent research provider, has provided MT Newswires with the following research alert. Analysts at CFRA have summarized their opinion as follows:

We raise our target price to USD121 from USD110 and our EPS estimates to USD8.58 from USD8.17 for 2025 and to USD8.90 from USD8.43 for 2026 in view of the strong Q1 and guidance upgrade. Our target price implies a 2025 P/E multiple of 14.1x, largely in line with its historical forward P/E multiple. We expect its key products to drive growth ahead, which includes Kesimpta and Kisqali on continued demand, as well as Pluvicto (estimated peak sales of USD5 billion+), which was recently approved in the pre-taxane setting (expanding the drug into earlier treatment of cancer, along with the existing approvals as a post-chemotherapy treatment). In our view, the 40%+ margin target by 2027 (2024: 38.7%) seems attainable, with cost control and productivity improvement supporting margins as seen in Q1, though we are mindful of new launch-related costs.